FDA Approves Pricey New Breast Cancer Drug

Full course of Roche's Kadcyla will cost $94K

By Newser Editors and Wire Services

Posted Feb 22, 2013 12:20 PM CST

(Newser) – The FDA has approved a first-of-a-kind breast cancer medication that targets tumor cells while sparing healthy ones. The drug Kadcyla from Roche combines the established drug Herceptin with a powerful chemotherapy drug and a third chemical linking the medicines together. The chemical keeps the cocktail intact until it binds to a cancer cell, delivering a double-shot of anti-tumor poison. Cancer researchers say the drug, which will cost nearly $10,000 a month, may offer a clear advantage over older drugs because it delivers more medication with fewer side effects.

The FDA approved the new treatment for about 20% of breast cancer patients with a form of the disease that is typically more aggressive and less responsive to hormone therapy. These patients have tumors that overproduce a protein known as HER-2. The approval will help Roche's Genentech unit build on the blockbuster success of Herceptin, which has long dominated the breast cancer marketplace. The drug had sales of roughly $6 billion last year. Genentech said Kadcyla will cost $9,800 per month, compared to $4,500 per month for regular Herceptin. The company estimates a full course of Kadcyla, about nine months of medicine, will cost $94,000.

A file photo of Swiss pharmaceutics company Roche in Basel, Switzerland.
A file photo of Swiss pharmaceutics company Roche in Basel, Switzerland.   (AP Photo/Keystone, Steffen Schmidt)
« Prev« Prev | Next »Next » Slideshow
My TakeCLICK BELOW TO VOTE
2%
22%
11%
27%
11%
27%
To report an error on this story, notify our editors.

NEWS FROM OUR PARTNERS
Other Sites We Like:   The Street   |   24/7 Wall St.   |   BuzzFeed   |   Cracked   |   World History Project   |   POPSUGAR Tech   |   Business Insider   |   HuffPost Entertainment